Alternative medicine use in patients with localized prostate carcinoma treated with curative intent

Cancer

Volumn 86, Issue 12, 1999, Pages 2642-2648

  Lippert, Marguerite C ^a   McClain, Rebecca ^a   Boyd, James C ^a   Theodorescu, Dan ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Alternative medicine; Brachytherapy; Health surveys; Prostate neoplasms; Prostatectomy

Indexed keywords

BICALUTAMIDE; FINASTERIDE; FLUTAMIDE; HERBACEOUS AGENT; PROSTATE SPECIFIC ANTIGEN; VITAMIN;

ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; QUESTIONNAIRE; RELIGION; TREATMENT OUTCOME;

EID: 0033572780     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991215)86:12<2642::AID-CNCR8>3.0.CO;2-4     Document Type: Article

References (24)

1. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use [see comments]. N Engl J Med 1993;328(4):246-52.
2. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280(18):1569-75.
3. Cassileth BR, Chapman CC. Alternative and complementary cancer therapies. Cancer 1996;77(6):1026-34.
4. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systemic review. Cancer 1998;83(4):777-82.
5. DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Ran MM, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer [see comments]. N Engl J Med 1998;339(12):785-91.
6. Grignon DJ, Sakr WA. Pathologic staging of prostate carcinoma. What are the issues? Cancer 1996;78(2):337-40.
7. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111(1):58-64.
8. Horwitz EM, Vicini FA, Ziaja EL, Dmuchowski CF, Stromberg JS, Martinez AA. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 1998; 41(2):267-72.
9. Spiegel D, Moore R. Imagery and hypnosis in the treatment of cancer patients. Oncology (Huntingt) 1997;11(8):1179-89; discussion 1189-95.
10. Risberg T, Lund E, Wist E, Kaasa S, Wilsgaard T. Cancer patients use of nonproven therapy: a 5-year follow-up study [see comments]. J Clin Oncol 1998;16(1):6-12.
11. Lerner IJ, Kennedy BJ. The prevalence of questionable methods of cancer treatment in the United States. CA Cancer J Clin 1992;42(3):181-91.
12. Begbie SD, Kerestes ZL, Bell DR. Patterns of alternative medicine use by cancer patients [see comments]. Med J Aust 1996;165(10):545-8.
13. Downer SM, Cody MM, McCluskey P, Wilson PD, Arnott SJ, Lister TA, et al. Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment [see comments]. BMJ 1994;309(6947):86-9.
14. Cassileth BR, Chapman CC. Alternative cancer medicine: a ten-year update. Cancer Invest 1996;14(4):396-404.
15. Risberg T, Lund E, Wist E. Use of non-proven therapies. Differences in attitudes between Norwegian patients with non-malignant disease and patients suffering from cancer. Acta Oncol 1995;34(7):893-8.
16. Cassileth BR, Lusk EJ, Guerry D, Blake AD, Walsh WP, Kascius L, et al. Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy [see comments]. N Engl J Med 1991;324(17):1180-5.
17. Risberg T, Lund E, Wist E, Dahl O, Sundstrom S, Andersen OK, et al. The use of non-proven therapy among patients treated in Norwegian oncological departments. A cross-sectional national multicentre study. Eur J Cancer 1995;31A(11): 1785-9.
18. Cassileth BR, Lusk EJ, Strouse TB, Bodenheimer BJ. Contemporary unorthodox treatments in cancer medicine. A study of patients, treatments, and practitioners. Ann Intern Med 1984;101(1):105-12.
19. Nam RK, Fleshner N, Rakovitch E, Klotz L, Trachtenberg J, Choo K, et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol 1999;161(5):1521-4.
20. Eidinger RN, Schapira DV. Cancer patients' insight into their treatment, prognosis, and unconventional therapies. Cancer 1984;53(12):2736-40.
21. Saw palmetto for benign prostatic hyperplasia. The Medical Letter 1999;41(1046):18.
22. Carraro JC, Raynaud JP, Koch G, Chisholm GD, DiSilverio F, Teillac P, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29(4):231-40; discussion 241-2.
23. Zhang X, Habib FK, Ross M, Burger U, Lewenstein A, Rose K, et al. Isolation and characterization of a cyclic hydroxamic acid from a pollen extract, which inhibits cancerous cell growth in vitro. J Med Chem 1995;38(4):735-8.
24. Habib FK, Ross M, Lewenstein A, Zhang X, Jaton JC. Identification of a prostate inhibitory substance in a pollen extract. Prostate 1995;26(3):133-9.